DURATION OF ADJUVANT HORMONAL THERAPY IN PROSTATE CANCER PATIENTS

J Clin Oncol. 2009 Mar 23. [Epub ahead of print]

Related Articles, LinkOut

Impact of the Duration of Adjuvant Hormonal Therapy in Patients With Locally Advanced Prostate Cancer Treated With Radiotherapy: A Secondary Analysis of RTOG 85-31.

Souhami L, Bae K, Pilepich M, Sandler H.

McGill University Health Center, Montreal, Quebec, Canada; Radiation Therapy Oncology Group, Philadelphia, PA; University of California Medical Center, Los Angeles, CA; and University of Michigan, Ann Arbor, MI.

PURPOSE: Radiation Therapy Oncology Group 85-31 was a randomized trial of androgen suppression for life for patients with locally advanced prostate cancer. However, not all patients continued on the protocol-mandated long-term hormonal therapy despite no evidence of recurrence. We correlated duration of adjuvant hormonal therapy and outcomes among patients who prematurely discontinued hormonal therapy. PATIENTS AND METHODS: The protocol mandated pelvic radiotherapy followed by goserelin given indefinitely or until disease progression. There were 189 analyzable patients. Patients were divided in groups based on the tertile of hormonal therapy duration (HTD) as follows: